April 1, 2021
Bristol-Myers Squibb K.K. said on March 31 that its subsidiary Celgene K.K. has filed its second CAR-T cell therapy idecabtagene vicleucel (ide-cel) in Japan for the treatment of relapsed or refractory multiple myeloma. The announcement comes just over a week...read more